ADAP
Price
$0.74
Change
+$0.02 (+2.74%)
Updated
Sep 20, 6:59 PM EST
42 days until earnings call
AGIO
Price
$24.56
Change
-$0.51 (-2.03%)
Updated
Sep 20, 6:59 PM EST
42 days until earnings call

Analysis and predictions ADAP vs AGIO

Header iconADAP vs AGIO Comparison
Open Charts ADAP vs AGIOBanner chart's image
Adaptimmune Therapeutics
Price$0.74
Change+$0.02 (+2.74%)
Volume$124.49K
CapitalizationN/A
Agios Pharmaceuticals
Price$24.56
Change-$0.51 (-2.03%)
Volume$131.54K
CapitalizationN/A
View a ticker or compare two or three
ADAP vs AGIO Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
ADAP vs. AGIO commentary
Sep 21, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Hold and AGIO is a Hold.

COMPARISON
Comparison
Sep 21, 2023
Stock price -- (ADAP: $0.75 vs. AGIO: $24.56)
Brand notoriety: ADAP and AGIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 36% vs. AGIO: 68%
Market capitalization -- ADAP: $167.48M vs. AGIO: $1.42B
ADAP [@Biotechnology] is valued at $167.48M. AGIO’s [@Biotechnology] market capitalization is $1.42B. The market cap for tickers in the [@Biotechnology] industry ranges from $424.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 1 FA rating(s) are green whileAGIO’s FA Score has 0 green FA rating(s).

  • ADAP’s FA Score: 1 green, 4 red.
  • AGIO’s FA Score: 0 green, 5 red.
According to our system of comparison, AGIO is a better buy in the long-term than ADAP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 5 TA indicator(s) are bullish while AGIO’s TA Score has 5 bullish TA indicator(s).

  • ADAP’s TA Score: 5 bullish, 3 bearish.
  • AGIO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ADAP is a better buy in the short-term than AGIO.

Price Growth

ADAP (@Biotechnology) experienced а -7.26% price change this week, while AGIO (@Biotechnology) price change was -9.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.61%. For the same industry, the average monthly price growth was +23.29%, and the average quarterly price growth was +30.30%.

Reported Earning Dates

ADAP is expected to report earnings on Nov 02, 2023.

AGIO is expected to report earnings on Nov 02, 2023.

Industries' Descriptions

@Biotechnology (-1.61% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ADAP with price predictions.
OPEN
A.I.dvisor published
a Summary for AGIO with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
AGIO($1.42B) has a higher market cap than ADAP($167M). AGIO YTD gains are higher at: -12.536 vs. ADAP (-48.973). ADAP has higher annual earnings (EBITDA): -102.48M vs. AGIO (-367.18M). AGIO has more cash in the bank: 703M vs. ADAP (205M). ADAP has less debt than AGIO: ADAP (26.3M) vs AGIO (78.9M). ADAP has higher revenues than AGIO: ADAP (70.8M) vs AGIO (20.1M).
ADAPAGIOADAP / AGIO
Capitalization167M1.42B12%
EBITDA-102.48M-367.18M28%
Gain YTD-48.973-12.536391%
P/E RatioN/AN/A-
Revenue70.8M20.1M352%
Total Cash205M703M29%
Total Debt26.3M78.9M33%
FUNDAMENTALS RATINGS
ADAP vs AGIO: Fundamental Ratings
ADAP
AGIO
OUTLOOK RATING
1..100
366
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
48
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
8161
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADAP's Valuation (27) in the Biotechnology industry is in the same range as AGIO (48). This means that ADAP’s stock grew similarly to AGIO’s over the last 12 months.

ADAP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AGIO (100). This means that ADAP’s stock grew similarly to AGIO’s over the last 12 months.

AGIO's SMR Rating (94) in the Biotechnology industry is in the same range as ADAP (97). This means that AGIO’s stock grew similarly to ADAP’s over the last 12 months.

AGIO's Price Growth Rating (61) in the Biotechnology industry is in the same range as ADAP (81). This means that AGIO’s stock grew similarly to ADAP’s over the last 12 months.

AGIO's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ADAP (100). This means that AGIO’s stock grew similarly to ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPAGIO
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 1 day ago
70%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 8 days ago
83%
Bullish Trend 9 days ago
73%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 1 day ago
78%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SIIAX15.96N/A
N/A
AlphaCentric Strategic Income A
GGOIX17.04N/A
N/A
Goldman Sachs Mid Cap Growth Instl
IIGIX9.39N/A
N/A
Voya Multi-Manager International Eq I
RPMGX97.19-0.35
-0.36%
T. Rowe Price Mid-Cap Growth
GCECX14.30-0.11
-0.76%
AB Global Core Equity C

ADAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with ADPT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then ADPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
+2.41%
ADPT - ADAP
44%
Loosely correlated
-4.60%
ORMP - ADAP
36%
Loosely correlated
-3.83%
CYTK - ADAP
36%
Loosely correlated
-2.92%
NTLA - ADAP
32%
Poorly correlated
-1.11%
ABUS - ADAP
32%
Poorly correlated
+1.01%
More

AGIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AGIO has been loosely correlated with BEAM. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if AGIO jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGIO
1D Price
Change %
AGIO100%
-2.03%
BEAM - AGIO
60%
Loosely correlated
+2.98%
NTLA - AGIO
60%
Loosely correlated
-1.11%
RARE - AGIO
58%
Loosely correlated
-0.58%
EDIT - AGIO
58%
Loosely correlated
-0.50%
CRSP - AGIO
56%
Loosely correlated
-1.81%
More